Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

Hepatitis

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Lancet Gastroenterol Hepatol.

Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY

doi: 10.1016/S2468-1253(19)30421-2.

Hepatitis

Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study

Am J Gastroenterol.

Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N, Hepatitis B Research Network (HBRN).

doi: 10.14309/ajg.

Hepatitis

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

World J Gastroenterol.

Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, Group TTR

doi: 10.3748/wjg.v23.i41.7459.

Hepatitis

HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy

Hepatology

Mak LY, Cloherty G, Wong DK, Gersch J, Seto WK, Fung J, Yuen MF

doi: 10.1002/hep.31616

Hepatitis

Use of Hepatitis B Virus Core Related Antigen to Evaluate Natural History of Chronic Hepatitis B

J Gastroenterol Hepatol.

Chan HLY, Yasuda S, Wong GLH, Tada T, Chan CKM, Kumada T, Tse YK, Wong VWS, Toyoda H

doi: 10.1111/jgh.15058.

Hepatitis

Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes

BMC Gastroenterol.

Allard NL, MacLachlan JH, Dev A, Dwyer J, Srivatsa G, Spelman T, Thompson AJ, Cowie BC

doi: 10.1186/s12876-020-01219-w.

Hepatitis

Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial

Vaccine

Diaz-Mitoma F, Popovic V, Spaans JN

doi: 10.1016/j.vaccine.2021.05.067

Hepatitis

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

Gut.

Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA

doi: 10.1136/gutjnl-2019-318981.

Inflammatory Bowel Disease

Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease

Dig Dis Sci.

Pratt PK Jr, Nunes D, Long MT, Farraye FA

doi: 10.1007/s10620-

Related content

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy

Use of Hepatitis B Virus Core Related Antigen to Evaluate Natural History of Chronic Hepatitis B

Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes

Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease